Slide 1

What do we need to better understand

risk in personalising care in early HL ?

•

Risks models for assessing potential consequences of

radiation therapy delivery

• A

ge of patient (young vs older)

• Sex of the patient ( breast tissue in < 35 years))

• Site of disease (groin, neck, axilla vs mediastinum)

• Volume, field, dose, technique (IMRT, VMAT)

•

Risk models for assessing response to chemotherapy ?

• Internationally Reproducible Deauville scoring

• Internationally reliable PET QA

• Integration of clinical risk and /or other biomarkers

•

Risk models for assessing consequences of chemotherapy

• Bleomycin lung injury

• Anthracycline induced cardiac damage

• neuropathy